TY - JOUR
T1 - Association of Reaction Symptoms and Eliciting Dose With Health-Related Quality of Life in Children With Peanut Allergy
AU - Hu, Alice
AU - Lloyd, Melanie
AU - Loke, Paxton
AU - Chebar Lozinsky, Adriana
AU - O'Sullivan, Michael
AU - Quinn, Patrick
AU - Gold, Michael
AU - Tang, Mimi L.K.
N1 - Funding Information:
M.L.K. Tang declares consultant fees from Pfizer and Abbott Nutrition; inventorship on patents covering Probiotic and Peanut Oral Immunotherapy; being a past employee of and holding share interest and options in Prota Therapeutics; membership of the Medical Advisory Board of Anaphylaxis & Anaphylaxis Australia; membership of the Board of Directors of the Asia Pacific Association of Allergy Asthma and Clinical Immunology and past membership of the Board of Directors of the World Allergy Organization (ended 2019); membership of expert committees of the American Academy of Allergy Asthma and Immunology, Asia Pacific Association of Allergy Asthma and Clinical Immunology, and Australasian Society of Clinical Immunology and Allergy; and past membership of the International Union of Immunological Societies (ended 2019). M O'Sullivan reports having received grants from the Government of Western Australia Department of Health and Channel 7 Telethon Trust; and being a director of the Australasian Society of Clinical Immunology and Allergy. P Quinn reports having received grants from DBV Technologies. The rest of the authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2023 American Academy of Allergy, Asthma & Immunology
PY - 2023/10
Y1 - 2023/10
N2 - Background: Food allergy adversely affects the health-related quality of life (HRQoL) of patients. It is unclear whether factors such as the reaction eliciting dose (ED) and the nature of allergic reaction symptoms affect HRQoL. Objective: To explore associations between reaction ED or the nature of allergic symptoms and HRQoL among children with peanut allergy. Methods: This study was a secondary analysis of baseline data from the PPOIT-003 randomized trial in 212 children aged 1 to 10 years with challenge-confirmed peanut allergy. Children's past reaction symptoms were collected by clinicians during screening. Associations between variables of interest and parent-reported child-proxy HRQoL were examined by univariable and multivariable linear regression. Results: Mean age of study participants was 5.9 years; 63.2% were male. Children with a low reaction ED of 80 mg peanut protein had significantly poorer HRQoL (β = –0.81; 95% CI, –1.61 to –0.00; P = .049) compared with children with a high ED of 2,500 mg peanut protein. Gastrointestinal symptoms (β = 0.45; 95% CI, 0.03-0.87; P = .037), lower airway symptoms (β = 0.46; 95% CI, 0.05-0.87; P = .030), multisystem involvement (β = 0.71; 95% CI, 0.25-1.16; P = .003), or anaphylaxis (β = 0.46; 95% CI, 0.04-0.87; P = .031) during a previous reaction were associated with worse HRQoL. Conclusions: Peanut-allergic children with a lower allergen reaction threshold experienced a greater negative HRQoL impact compared with children with higher reaction thresholds. In addition, specific past allergic reaction symptoms were associated with comparatively worse HRQoL. Children experiencing these symptoms and those with lower reaction ED require increased clinical support to manage the food allergy and are likely to benefit from interventions that can improve HRQoL.
AB - Background: Food allergy adversely affects the health-related quality of life (HRQoL) of patients. It is unclear whether factors such as the reaction eliciting dose (ED) and the nature of allergic reaction symptoms affect HRQoL. Objective: To explore associations between reaction ED or the nature of allergic symptoms and HRQoL among children with peanut allergy. Methods: This study was a secondary analysis of baseline data from the PPOIT-003 randomized trial in 212 children aged 1 to 10 years with challenge-confirmed peanut allergy. Children's past reaction symptoms were collected by clinicians during screening. Associations between variables of interest and parent-reported child-proxy HRQoL were examined by univariable and multivariable linear regression. Results: Mean age of study participants was 5.9 years; 63.2% were male. Children with a low reaction ED of 80 mg peanut protein had significantly poorer HRQoL (β = –0.81; 95% CI, –1.61 to –0.00; P = .049) compared with children with a high ED of 2,500 mg peanut protein. Gastrointestinal symptoms (β = 0.45; 95% CI, 0.03-0.87; P = .037), lower airway symptoms (β = 0.46; 95% CI, 0.05-0.87; P = .030), multisystem involvement (β = 0.71; 95% CI, 0.25-1.16; P = .003), or anaphylaxis (β = 0.46; 95% CI, 0.04-0.87; P = .031) during a previous reaction were associated with worse HRQoL. Conclusions: Peanut-allergic children with a lower allergen reaction threshold experienced a greater negative HRQoL impact compared with children with higher reaction thresholds. In addition, specific past allergic reaction symptoms were associated with comparatively worse HRQoL. Children experiencing these symptoms and those with lower reaction ED require increased clinical support to manage the food allergy and are likely to benefit from interventions that can improve HRQoL.
KW - Allergic reaction symptoms
KW - Eliciting dose
KW - Food allergy
KW - Peanut allergy
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85165650594&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2023.06.063
DO - 10.1016/j.jaip.2023.06.063
M3 - Article
C2 - 37423341
AN - SCOPUS:85165650594
SN - 2213-2198
VL - 11
SP - 3195-3202.e4
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
IS - 10
ER -